Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.51 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.48 |
| ▸ | FABP3 | P05413 | 1/20 | 0.46 |
| ▸ | FABP4 | P15090 | 1/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 8/20 | 0.46 |
| ▸ | PPARD | Q03181 | 3/20 | 0.46 |
| ▸ | PPARA | Q07869 | 3/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | SLC26A4 | O43511 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5111750 | 0.87 | NR4A2 (0.45) | PPARGNR4A2FABP3FABP4FABP5 | |
| SCHEMBL3210357 | 0.85 | LMNA (0.47) | NR4A2FABP3FABP4FABP5NR4A1 | |
| SCHEMBL3212783 | 0.84 | NR4A2 (0.45) | PPARGNR4A2FABP3FABP4FABP5 | |
| SCHEMBL5109103 | 0.83 | PPARG (0.54) | PPARGNR4A2PTGDRFFAR1PTGER1 | |
| SCHEMBL5107321 | 0.82 | PPARG (0.59) | PPARGPTGER1 | |
| SCHEMBL5105830 | 0.81 | PPARG (0.52) | PPARGFABP3FABP4FFAR4PPARD | |
| SCHEMBL5111643 | 0.81 | PPARG (0.59) | PPARGPTGER1 | |
| SCHEMBL3219179 | 0.79 | PPARG (0.64) | PPARG | |
| SCHEMBL5113115 | 0.79 | PPARG (0.46) | PPARGNR4A2PTGDRFABP3FABP4 | |
| SCHEMBL15211124 | 0.77 | FFAR1 (0.72) | NR4A2FFAR1FFAR4NR4A1NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041892-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2010-02-18 | — | — | US | disclosed |
| US-20090270631-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2009-10-29 | — | — | US | disclosed |
| EP-1912645-A2 | THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
| WO-2007018314-A2 | THERAPEUTIC AGENT FOR DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270631-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | PPARG 31/4885NR4A2 1552/4885PTGDR 1144/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | PPARG 30/4885NR4A2 1322/4885PTGDR 939/4885 |
| US-20100041892-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | PPARG 31/4885NR4A2 1552/4885PTGDR 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.